Evidence map›Paper›PMID 42627648›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Unified Hierarchical Multiscale Fusion Framework for Drug-Target Affinity Prediction: From Benchmark Performance to Nanomolar Inhibitor Discovery.

Shuo Liu, Xiang Zhang, Haixia Feng, Yuquan Li, Xiaoqing Gong, Yong Liang, Xiaojun Yao, Huanxiang Liu

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuo LiuChinese Medicine Guangdong Laboratory (Hengqin Laboratory), Guangdong-Macao In-Depth Cooperation Zone in Hengqin, Guangdong, China.
Xiang ZhangChinese Medicine Guangdong Laboratory (Hengqin Laboratory), Guangdong-Macao In-Depth Cooperation Zone in Hengqin, Guangdong, China.ORCID https://orcid.org/0009-0008-0967-5262
Haixia FengChinese Medicine Guangdong Laboratory (Hengqin Laboratory), Guangdong-Macao In-Depth Cooperation Zone in Hengqin, Guangdong, China.
Yuquan LiState Key Laboratory of Public Big Data, College of Computer Science and Technology, Guizhou University, Guiyang, China.ORCID https://orcid.org/0000-0003-2756-0449
Xiaoqing GongFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Yong LiangChinese Medicine Guangdong Laboratory (Hengqin Laboratory), Guangdong-Macao In-Depth Cooperation Zone in Hengqin, Guangdong, China.
Xiaojun YaoFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.ORCID https://orcid.org/0000-0002-8974-0173
Huanxiang LiuFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.ORCID https://orcid.org/0000-0002-9284-3667

Funding

Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine ZYYCXTD-D-202403Macao Science and Technology Development Fund 0043/2023/AFJScience and Technology Research and Development Cultivation Project HQL2025KPA00103Scientific research start-up funds of Chinese Medicine Guangdong Laboratory HQL2025SU030
6 · The paper itself

Abstract

Accurately predicting drug-target affinity (DTA) is crucial for accelerating virtual screening and guiding lead optimization in drug discovery. However, current computational approaches face a critical trade-off: interaction-free models lack fine-grained binding details, while interaction-based models overlook higher-order contextual and functional patterns. This limitation hinders both prediction performance and real-world generalization. To overcome this, we propose MF-Net, a unified hierarchical multiscale fusion framework that integrates sequence-, atomic-, and fragment-level representations to model drug-target interactions across complementary scales. MF-Net achieves state-of-the-art performance on the PDBBind v2016 benchmark and demonstrates strong early enrichment across multiple virtual screening datasets. Additionally, ADP-Glo assays confirm that the MF-Net-guided virtual screening pipeline identifies seven novel nanomolar inhibitors targeting hematopoietic progenitor kinase 1 (HPK1). Among them, one compound achieves sub-nanomolar activity (IC

Indexed as

contrastive learningdrug–target affinity predictionHPK1 inhibitorslead identificationmultimodal fusion

Identifiers

PMID42627648
PMCPMC13496275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.